Welcome to MediciNova
MediciNova in the News
National Asthma Awareness Month: What's Next in the Treatment of Acute Asthma?
San Diego's MediciNova Nears Turning Point with Lead Drug for Asthma - May 8, 2012
Click to read about Dr. Iwaki, President & CEO of MediciNova, feautred in PharmaVoice May 2012
Click to watch a segment featuring MN-221 by NBC Philadelphia.
MediciNova Featured on NBC's Better Life Guide - Biotech N' You
Click for more information on our Core Candidates:
- MN-221 (Exacerbations of Asthma/COPD)
- Ibudilast (Neuropathic Pain, Drug Addiction, and Multiple Sclerosis)
MN-221 Update:
March 22 , 2012 - MediciNova, Inc. announced it has completed enrollment in its Phase 2 clinical trial (MN-221-CL-007) evaluating the safety and efficacy of MN-221 for treatment of acute exacerbations of asthma.
MediciNova's Corporate Presentation
About MediciNova
MediciNova, Inc. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet need with a specific focus on the U.S. market.
Order Preliminarily Approving Settlement and Providing for Notice
